Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)
- Authors
- Sun, Jong-Mu; Lee, Ki Hyeong; Kim, Sang-we; Lee, Dae Ho; Min, Young Joo; Yun, Hwan Jung; Kim, Hoon Kyo; Song, Hong Suk; Kim, Yeul Hong; Kim, Bong-Seog; Hwang, In Gyu; Lee, Keehyun; Jo, Sook Jung; Lee, Jae Won; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju
- Issue Date
- 15-Dec-2012
- Publisher
- WILEY-BLACKWELL
- Keywords
- gefitinib; pemetrexed; nonsmall cell lung cancer
- Citation
- CANCER, v.118, no.24, pp 6234 - 6242
- Pages
- 9
- Journal Title
- CANCER
- Volume
- 118
- Number
- 24
- Start Page
- 6234
- End Page
- 6242
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/19937
- DOI
- 10.1002/cncr.27630
- ISSN
- 0008-543X
1097-0142
- Abstract
- BACKGROUND: Gefitinib was compared with pemetrexed as second-line therapy in a clinically selected population previously treated with platinum-based chemotherapy. METHODS: A phase 3 trial of gefitinib (250 mg/day) versus pemetrexed (500 mg/m(2) on day 1, every 3 weeks) was conducted in patients who had never smoked and who had advanced pulmonary adenocarcinoma treated with 1 previous platinum-based regimen. The primary endpoint was progression-free survival (PFS). RESULTS: A total of 135 patients were analyzed. The gefitinib group had significantly longer PFS compared with the pemetrexed group, with a median PFS time of 9.0 versus 3.0 months (P = .0006). The objective response rates were 58.8% and 22.4% for gefitinib and pemetrexed, respectively (P < .001). However, there was no statistically significant difference in overall survival between the 2 groups (22.2 vs 18.9 months; P = .37). The difference of PFS was increased in a subgroup analysis of 33 patients with activating epidermal growth factor receptor mutation (15.7 vs 2.9 months; hazard ratio, 0.3; 95% confidence interval, 0.13-0.72; P = .005), with numerical superiority of gefitinib in the 38 patients testing negative for epidermal growth factor receptor mutation (5.9 vs 2.7 months; P = .099). Both regimens were well tolerated. There were no significantly different changes in quality of life between the 2 groups, except that symptom scores for dyspnea and diarrhea favored the gefitinib and pemetrexed arms, respectively. CONCLUSIONS: Gefitinib showed superior efficacy to pemetrexed as second-line therapy in Korean never-smokers with pulmonary adenocarcinoma. Cancer 2012; 118:6234-42. (C) 2012 American Cancer Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/19937)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.